THE USE OF GENE EXPRESSION PROFILES TO PREDICT THE RESPONSE TO CHEMORADIOTHERAPY IN PATIENT WITH OESOPHAGEAL CANCER

Abstract

One of the most difficult and clinically important questions facing clinicians treating advanced cancer is deciding which patients will, and who will not, benefit from chemotherapy and-or radiotherapy. This is particularly true for clinicians treating locally advanced oesophageal cancer. Oesophageal cancer is a particularly aggressive tumour with a poor prognosis; the majority of patients die within 1 year of diagnosis with only 10% surviving to 5 years. In an attempt to improve outcomes, the use of preoperative (neoadjuvant) combined chemotherapy and radiotherapy as an adjunct to surgery has become common practice. Neoadjuvant therapy has been reported to induce complete regression of the t..

Related publications (1)

Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer

Cuong Duong, Danielle M Greenawalt, Adam Kowalczyk, Marianne L Ciavarella, Garvesh Raskutti, William K Murray, Wayne A Phillips, Robert JS Thomas

2007-12-01

BACKGROUND: The use of neoadjuvant therapy, in particular chemoradiotherapy (CRT), in the treatment of esophageal cancer (EC) rema..